Tirzepatide is a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, used for the treatment of type 2 diabetes and obesity, and recently approved for obstructive sleep apnea. This evidence concerns the gene GIP and obstructive sleep apnea syndrome.